Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors

被引:2
作者
Schuettke, Vayda [1 ,2 ]
Kusiek, Cathrin [1 ,2 ]
Fuessel, Susanne [1 ,2 ,3 ,4 ]
Thomas, Christian [1 ,2 ]
Buerk, Bjoern Thorben [1 ,2 ]
Erdmann, Kati [1 ,2 ,3 ,4 ]
机构
[1] Tech Univ Dresden, Fac Med, Dept Urol, Dresden, Germany
[2] Univ Hosp Carl Gustav Carus, Dresden, Germany
[3] German Canc Consortium DKTK, Partner Site Dresden, Dresden, Germany
[4] German Canc Res Ctr, Heidelberg, Germany
关键词
Biomarker; CRP kinetics; Immunotherapy; Metastatic renal cell carcinoma; Prognosis; Tyrosine kinase inhibitors; GROWTH-FACTOR; INTERLEUKIN-6; IL-6;
D O I
10.1007/s12094-023-03317-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study investigated the prognostic potential of baseline C-reactive protein (CRP) levels and early CRP kinetics in a real-world cohort of patients with metastatic renal cell carcinoma (mRCC) under first-line (1L) therapy with immune checkpoint inhibitors (CPI). Methods/patients Analyses were performed retrospectively in a cohort of 61 mRCC patients under CPI-based 1L therapy. Patients were stratified based on baseline CRP (< 10 vs >= 10 mg/l) and CRP change within the initial three months of CPI therapy (normal: baseline < 10 mg/l, normalized: baseline >= 10 mg/l and nadir < 10 mg/l, non-normalized: baseline and nadir >= 10 mg/l). Finally, the association of baseline CRP and CRP change with progression-free (PFS) and overall survival (OS) was evaluated. Results Baseline CRP was not significantly associated with both PFS (p = 0.666) and OS (p = 0.143). Following stratification according to early CRP kinetics, 23, 25 and 13 patients exhibited normal, normalized and non-normalized CRP levels, respectively. Patients with normal and normalized CRP had a markedly prolonged PFS (p = 0.091) and OS (p = 0.008) compared to patients with non-normalized CRP. Consequently, significantly better PFS (p = 0.031) and OS (p = 0.002) were observed for the combined normal-normalized group. In multivariate analysis including ECOG and IMDC risk, normalized CRP kinetics alone or in combination with the normal group was identified as significant independent risk factor for OS, whereas a statistical trend was observed for PFS. Conclusions The present study emphasizes the prognostic potential of early CRP kinetics in CPI-treated mRCC. As a standard laboratory parameter, CRP can be easily implemented into clinical routine to facilitate therapy monitoring.
引用
收藏
页码:1117 / 1128
页数:12
相关论文
共 31 条
[1]   IL-6 as an intracrine growth factor for renal carcinoma cell lines [J].
Alberti, L ;
Thomachot, MC ;
Bachelot, T ;
Menetrier-Caux, C ;
Puisieux, I ;
Blay, JY .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (05) :653-661
[2]   Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma [J].
Bedke, Jens ;
Albiges, Laurence ;
Capitanio, Umberto ;
Giles, Rachel H. ;
Hora, Milan ;
Lam, Thomas B. ;
Ljungberg, Borje ;
Marconi, Lorenzo ;
Klatte, Tobias ;
Volpe, Alessandro ;
Abu-Ghanem, Yasmin ;
Dabestani, Saeed ;
Fernandez-Pello, Sergio ;
Hofmann, Fabian ;
Kuusk, Teele ;
Tahbaz, Rana ;
Powles, Thomas ;
Bex, Axel .
EUROPEAN UROLOGY, 2021, 79 (03) :339-342
[3]   Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters [J].
Del Giudice, Marco ;
Gangestad, Steven W. .
BRAIN BEHAVIOR AND IMMUNITY, 2018, 70 :61-75
[4]   Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab [J].
Fukuda, Shohei ;
Saito, Kazutaka ;
Yasuda, Yosuke ;
Kijima, Toshiki ;
Yoshida, Soichiro ;
Yokoyama, Minato ;
Ishioka, Junichiro ;
Matsuoka, Yoh ;
Kageyama, Yukio ;
Fujii, Yasuhisa .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
[5]   Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma [J].
Ishihara, Hiroki ;
Takagi, Toshio ;
Kondo, Tsunenori ;
Fukuda, Hironori ;
Tachibana, Hidekazu ;
Yoshida, Kazuhiko ;
Iizuka, Junpei ;
Okumi, Masayoshi ;
Ishida, Hideki ;
Tanabe, Kazunari .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (05) :526-532
[6]   Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma [J].
Ishihara, Hiroki ;
Tachibana, Hidekazu ;
Takagi, Toshio ;
Kondo, Tsunenori ;
Fukuda, Hironori ;
Yoshida, Kazuhiko ;
Iizuka, Junpei ;
Kobayashi, Hirohito ;
Okumi, Masayoshi ;
Ishida, Hideki ;
Tanabe, Kazunari .
TARGETED ONCOLOGY, 2019, 14 (04) :453-463
[7]   Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue [J].
Jabs, WJ ;
Busse, M ;
Krüger, S ;
Jocham, D ;
Steinhoff, J ;
Doehn, C .
KIDNEY INTERNATIONAL, 2005, 68 (05) :2103-2110
[8]   C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients [J].
Kankkunen, Elisa ;
Penttila, Patrick ;
Peltola, Katriina ;
Bono, Petri .
ACTA ONCOLOGICA, 2022, 61 (10) :1240-1247
[9]   C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma [J].
Kluemper, Niklas ;
Sikic, Danijel ;
Saal, Jonas ;
Buettner, Thomas ;
Goldschmidt, Franziska ;
Jarczyk, Jonas ;
Becker, Philippe ;
Zeuschner, Philip ;
Weinke, Maximilian ;
Kalogirou, Charis ;
Breyer, Johannes ;
Burger, Maximilian ;
Nuhn, Philipp ;
Tully, Karl ;
Roghmann, Florian ;
Bolenz, Christian ;
Zengerling, Friedemann ;
Wirtz, Ralph M. ;
Muders, Michael ;
Kristiansen, Glen ;
Bald, Tobias ;
Ellinger, Joerg ;
Wullich, Bernd ;
Hoelzel, Michael ;
Hartmann, Arndt ;
Erben, Philipp ;
Ritter, Manuel ;
Eckstein, Markus .
EUROPEAN JOURNAL OF CANCER, 2022, 167 :13-22
[10]   C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer [J].
Kluemper, Niklas ;
Saal, Jonas ;
Berner, Fiamma ;
Lichtensteiger, Christa ;
Wyss, Nina ;
Heine, Annkristin ;
Bauernfeind, Franz Georg ;
Ellinger, Joerg ;
Brossart, Peter ;
Diem, Stefan ;
Schmid, Sabine ;
Joerger, Markus ;
Frueh, Martin ;
Ritter, Manuel ;
Hoelzel, Michael ;
Flatz, Lukas ;
Bald, Tobias .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)